Hepatic Elimination

Hepatic elimination is the removal of drugs by the liver through metabolism and biliary secretion. Its efficiency is captured by hepatic clearance, which physiological models express in terms of three quantities: liver blood flow, the unbound drug fraction, and the liver's intrinsic capacity to metabolize the drug. Whether a drug is flow-limited or capacity-limited depends on how these combine.

Definition

Hepatic elimination is the irreversible removal of drug by the liver via metabolism and biliary excretion, quantified as hepatic clearance and described physiologically by liver blood flow, unbound fraction, and intrinsic clearance.

Scope

This entry covers the physiological models of hepatic clearance, the extraction ratio and first-pass concept, the roles of drug-metabolizing enzymes and hepatic uptake transporters, and what limits clearance. It treats hepatic elimination as a pharmacokinetic process for reference; it is not dosing guidance for liver disease.

Core questions

• How do liver blood flow, protein binding, and intrinsic clearance jointly determine hepatic clearance?
• What distinguishes a high-extraction (flow-limited) from a low-extraction (capacity-limited) drug?
• How do the 'well-stirred' and 'parallel-tube' models of the liver differ in their predictions?
• How do hepatic uptake transporters and metabolic enzymes together govern elimination?

Key concepts

• Hepatic clearance
• Extraction ratio
• First-pass metabolism
• Intrinsic clearance
• Flow-limited versus capacity-limited elimination
• Hepatic uptake transporters
• Protein binding

Key theories

Well-stirred (venous equilibrium) model of hepatic clearance

The liver is treated as a single well-mixed compartment in which the drug concentration driving metabolism equals the unbound concentration leaving the organ, giving hepatic clearance as a function of blood flow, unbound fraction, and intrinsic clearance.

Parallel-tube (sinusoidal) model of hepatic clearance

The liver is modelled as a set of parallel tubes along which drug concentration declines from inlet to outlet, predicting somewhat different sensitivity of clearance to changes in flow and intrinsic clearance than the well-stirred model.

Mechanisms

Blood entering the liver carries drug that may be taken up into hepatocytes (often by uptake transporters such as OATP1B1), metabolized by drug-metabolizing enzymes, and secreted into bile. Physiological clearance models combine three determinants — hepatic blood flow, the unbound fraction of drug, and intrinsic clearance (the metabolic capacity were access unrestricted) — into the extraction ratio, the fraction of drug removed in a single pass. For high-extraction drugs, clearance approaches and is limited by blood flow, so changes in enzyme activity or binding matter little; for low-extraction drugs, clearance is limited by intrinsic clearance and unbound fraction, so enzyme induction or inhibition and changes in binding have large effects. Drug presented to the liver before reaching the systemic circulation may undergo extensive first-pass metabolism, reducing the amount that becomes available.

Clinical relevance

Hepatic elimination explains why some drugs show large first-pass loss, why enzyme inhibition or induction changes exposure mainly for low-extraction drugs, and why liver disease alters drug handling. The topic supports interpretation of pharmacokinetic and drug-interaction studies; it describes mechanisms for reference and is not a basis for individual dosing.

Evidence & guidelines

The physiological clearance framework rests on the foundational analyses of Wilkinson and Shand and of Pang and Rowland, who defined the extraction ratio and the competing liver models. The contribution of hepatic uptake transporters such as OATP1B1 is reviewed by Niemi and colleagues, and methods for estimating intrinsic clearance in vitro, including correction for microsomal binding, are addressed by Austin and colleagues.

History

The modern view of hepatic elimination emerged in 1975 when Wilkinson and Shand reframed liver drug removal in terms of flow, binding, and intrinsic clearance, and in 1977 when Pang and Rowland formalized the well-stirred and parallel-tube models. From the 1990s onward the molecular characterization of cytochrome P450 enzymes and hepatic transporters added a mechanistic layer to these physiological models.

Debates

Which physiological model of the liver best predicts hepatic clearance?

The well-stirred and parallel-tube models make different predictions for how clearance responds to changes in flow, binding, and intrinsic clearance, particularly for high-extraction drugs, and which model is most appropriate remains a methodological discussion.

Key figures

• Grant Wilkinson
• K. Sandy Pang
• Malcolm Rowland
• Mikko Niemi

Seminal works

• wilkinson-shand-1975
• pang-rowland-1977
• rowland-tozer-2011

Frequently asked questions

What is a high-extraction drug?

It is a drug the liver removes very efficiently in a single pass, so its hepatic clearance is limited mainly by how fast blood delivers it to the liver rather than by enzyme activity.

Why does enzyme inhibition affect some drugs more than others?

Inhibiting metabolism mainly changes clearance for low-extraction (capacity-limited) drugs, whose clearance depends on intrinsic metabolic activity; high-extraction drugs are limited by blood flow and are less sensitive to such changes.